眾生藥業(002317.SZ):用於治療成人單純性甲型流感的一類創新藥物ZSP1273片正處於III期臨牀試驗階段
格隆匯12月22日丨眾生藥業(002317.SZ)發佈股票交易異常波動公吿,公司用於治療成人單純性甲型流感的一類創新藥物ZSP1273片正處於III期臨牀試驗階段,公司將持續關注國內甲流流行動態,與各臨牀研究中心和合作單位保持密切聯繫和溝通,加大甲流受試者招募和篩選力度,積極促進入組工作,並採取有力措施推進ZSP1273片III期臨牀試驗進程。公司口服抗新型冠狀病毒3CL蛋白酶抑制劑RAY1216,其用於治療輕型和普通型SARS-CoV-2感染患者的隨機、雙盲、安慰劑對照III期臨牀研究方案已獲得組長單位廣州醫科大學附屬第一醫院醫學倫理委員會臨牀試驗快速審查批件,批准項目開展,目前正在開展III期臨牀研究。鑑於臨牀試驗研究具有周期長、投入大的特點,存在研發項目推進及研發效果不達預期的風險,創新藥的臨牀試驗進度、審評和審批的結果以及未來產品市場競爭格局都具有一定的不確定性;藥品能否獲批上市以及獲批上市的時間、上市後的生產和銷售情況存在不確定性。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.